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Abstract
Pulmonary embolism as a part of venous thromboem-
bolic disease has a broad spectrum of clinical presenta-
tions from minimal disease to life-threatening right heart
failure. Therapy has to be guided by the risk associated
with the individual clinical state of the patient. As long as
hemodynamics are entirely stable, anticoagulation is
given in order to prevent early or late recurrence, thereby
allowing for endogeneous thrombolysis and recovery. In
hemodynamically instable patients, i.e. patients under
cardiopulmonary resuscitation or in shock, there is the
need for a rapid reduction of thrombus mass in order to
restore right ventricular function. Systemic thrombolysis
is the most feasible modality to reduce the thrombus
burden of the pulmonary circulation in the short term.
For hemodynamically stable patients with right ventricu-
lar dysfunction as assessed by echocardiography, there
is still some controversy as to whether thrombolysis
improves the long-term outcome. At the least, thrombo-
lysis may positively modify the short-term course of
acute disease in patients with an extremely low risk of
bleeding. When the acute phase has been overcome,
secondary prophylaxis with vitamin K antagonists has to
be given. The duration of secondary prophylaxis re-
quires an individual assessment of both the risk of recur-
rence and the risk of bleeding. In the near future, new
anticoagulant drugs such as direct thrombin and factor
Xa inhibitors will offer new treatment modalities for the
acute phase as well as for secondary prophylaxis.
Copyright © 2003 S. Karger AG, Basel
Introduction
Pulmonary embolism (PE) may be considered a mani-
festation of a more complex disease, i.e. venous throm-
boembolic disease. Two basic facts justify this concept.
Firstly, in more than 90% of patients with PE, the origin
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of the thrombus can be found as deep venous thrombosis
(DVT) of the leg veins. Secondly, in more than 50% of all
DVT patients without signs and symptoms of PE, perfu-
sion defects are present on a lung scan. Considering
venous thromboembolic disease as a unifying concept, it
is plausible that treatment of this disease should be to
some extent uniform. Indeed, most of the data regarding
therapy of PE are shared with data referring to DVT. In
some aspects, treatment recommendations for PE are
merely extrapolated from evidence established for DVT,
since those aspects have not been studied separately for
PE.
On the other hand, PE may be very different from
DVT. This is particularly true if PE leads to hemody-
namic sequelae by stressing the right heart on a broad
spectrum of degrees of severity from mild increase of right
ventricular afterload to frank right heart failure. Thera-
peutic measures in this situation are directed towards
decreasing right ventricular afterload, which may be ac-
complished by decreasing thrombus mass in the pulmo-
nary arteries. The following paragraphs review all modali-
ties for the treatment of PE. Finally, an integrated concept
covering all clinical presentations of PE will be dis-
cussed.
Initial Anticoagulation
In 1960, Barritt and Jordan [1] published a random-
ized trial about the treatment of PE. Remarkably enough,
they randomized patients with acute PE into a treatment
arm, consisting of anticoagulation with heparin followed
by a 2-week course of a vitamin K antagonist (VKA), or
no treatment at all [1]. In those days, at a time without
established pharmacological thromboprophylaxis, the
fear of refractory bleeding induced by the use of anticoag-
ulants early after an operation was much greater than the
fear of even life-threatening venous thromboembolism
(VTE). For that reason, no ethical objections were made
against this otherwise methodologically sound trial. It was
probably due to the same reason that the authors ex-
pressed surprise when they found they had to stop the trial
after randomizing 35 patients, of whom 19 had received
no treatment and 16 had been treated with anticoagu-
lants. Five patients without treatment had died from
recurrent PE, and another 5 had suffered nonfatal recur-
rence, while among the patients on anticoagulants, no
fatal or nonfatal PE had occurred. After the first 35
patients, randomization was stopped and the treatment
arm of the study continued to a total of 54 patients; only
one nonfatal recurrence of PE and one episode of fatal
bleeding associated with unduly long prolongation of pro-
thrombin time were reported.
Even without sample size or power calculation, this
trial provided evidence strong enough to establish anti-
coagulation as the routine treatment in patients with con-
firmed PE. This treatment was extrapolated to benefit
patients with DVT as well, and no further trials on this
topic were ever conducted.
Over the next 25 years, trials on anticoagulation did
not specifically refer to patients with PE but were con-
ducted within a more comprehensive concept which con-
sidered DVT and PE as different manifestations of the
same disease. The classic sequence of unfractionated hep-
arin (UFH) followed by VKAs was refined in several
aspects: (1) UFH dosage should be guided by monitoring
activated partial thromboplastin time (aPTT), with a pro-
longation of 1.5–2.0 times the upper limit of normal being
appropriate [2]; (2) subcutaneous instead of intravenous
administration of UFH is adequate provided that aPTT is
monitored according to an appropriate time schedule [3];
(3) dose adjustments of UFH should ideally follow a pre-
defined decision rule, so-called nomograms, indicating
the appropriate change of dosage in response to aPTT
deviation from the target range – proposals for such
nomograms including validation trials have been made
until very recently [4, 5]; (4) UFH administration does
not need to be extended beyond 10 or more days, and 5
days are generally sufficient [6], and (5) even if VKAs are
started on the day of diagnosis, the concurrent adminis-
tration of heparin for the first 5 days is necessary to effec-
tively treat VTE [7].
These evidence-based refinements of initial anticoagu-
lation therapy had certainly not completely penetrated
current practice in the Western world when, in the early
1990s, the development of low-molecular-weight heparins
(LMWHs) moved from thromboprophylaxis to thera-
peutic indications. For regulatory reasons, LMWHs were
tested first in patients presenting with DVT. It was not
until 1997 that two trials also included patients presenting
with PE.
The COLUMBUS trial included 1,021 patients cover-
ing the full spectrum of VTE from isolated calf vein
thrombosis to symptomatic PE, randomizing them either
to classical anticoagulation with UFH or the LMWH revi-
parin, followed by a VKA [8]. 27% of all patients had pre-
sented with signs or symptoms of PE. The overall result of
the trial was within the range of all comparable studies
testing LMWHs against UFH and found no significant
difference regarding the endpoints of recurrence, major
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bleed and death after 90 days of follow-up. Regarding the
subgroup of patients with PE, the result was exactly the
same as for the entire patient population. However, the
sample size of this subgroup was not sufficiently powered
to draw firm conclusions on patients presenting with PE.
At exactly the same point in time, the Tinzaparine ou
Heparine Standard: Evaluations dans l’Embolie Pulmo-
naire study was published [9]. A comparison between
LWMH and UFH, this trial exclusively enrolled patients
presenting with signs and symptoms of PE. Of 612
patients, 47% had vascular obstruction of the pulmonary
circulation of more than 50%, mainly calculated by qual-
ifying perfusion lung scans at study entry. However,
patients in an unstable condition with overt or imminent
circulatory or respiratory failure were excluded. Patients
were randomized between body weight-adjusted subcuta-
neous LMWH (tinzaparin) once daily and intravenous
UFH; both regimens were followed by treatment with a
VKA for 90 days. The event rates for recurrence, major
bleed and death were unexpectedly low and showed no
significant differences between the LMWH and UFH.
However, the study was not sufficiently powered for a for-
mal equivalence analysis.
No trials testing any other LWMH for the treatment of
PE have been performed, and most probably never will
be. However, in subsequent years, the data from those two
studies helped establish the growing evidence which
showed the relative efficacy and safety of LMWHs in the
initial treatment of VTE. A recent meta-analysis of 14
randomized controlled trials comparing LMWHs to UFH
concluded that LMWHs are superior to UFH regarding
the endpoint of major bleeding [10]. A strong trend
towards superiority – albeit not statistically significant –
was also found regarding recurrent thromboembolic
events. The superiority of LMWHs found with respect to
mortality was achieved exclusively in a subgroup of
patients with cancer and VTE. This observation gave rise
to new study hypotheses about possible tumor-modulat-
ing effects of LMWHs. Thus, the current understanding
of initial anticoagulation of PE can be summarized as fol-
lows: As PE is one manifestation of venous thromboem-
bolic disease, the evidence from all methodologically
sound LMWH trials applies to this particular manifesta-
tion as well as to the entire spectrum of the disease. This
indicates that LMWHs in therapeutic doses are at least as
safe and effective as UFH in the initial anticoagulation of
PE and should be considered the current standard of ther-
apy. This holds true in particular in the light of the phar-
macokinetic properties of LMWHs, mainly their high bio-
availability and longer half-life, which allow once or twice
Table 1. Body weight-adjusted dosage of LMWHs in the therapy of
VTE
LMWH Dosage
Certoparin1 8,000 IE bid (Mono-Embolex®)
Dalteparin1 100 IE/kg bw bid (Fragmin®)
200 IE/kg bw od (Fragmin®)
Enoxaparin1 1 mg/kg bw bid (Clexane®)
Nadroparin1 0.1 ml/10 kg bw bid (Fraxiparin®)
0.1 ml/10 kg bw od (Fraxodi®)
Reviparin1 87.5 IE/kg bw bid (Clivarin®)
Tinzaparin 175 IE/kg bw od (Innohep®)
Observed drug information regarding body weight classes and
maximal dosage. bw = Body weight; od = once daily; bid = twice
daily.
1 Not explicitly approved for treatment of PE.
daily subcutaneous administration without laboratory
monitoring and dose adjustment (fig. 1).
Two major limitations have to be borne in mind. First-
ly, LMWHs have been tested only in patients without
severe impairment of renal function. Elimination of
LMWHs is primarily renal, so the possibility of accumula-
tion and overdosing has to be considered in patients with
impaired renal function. There is no established dose
adjustment regimen for different degrees of renal impair-
ment for any of the LMWHs. Thus, patients with a serum
creatinine of 1180 Ìmol/l (2.0 mg/dl) should be treated
with UFH and the traditional aPTT-guided dose adjust-
ment instead of an LMWH. The second limitation refers to
the clinical presentation of PE. All PE patients included in
clinical trials with LMWHs were, as a result of the exclu-
sion criteria, in a stable condition without any need for
catecholamines, mechanical ventilation or cardiopul-
monary resuscitation (CPR). For this reason, the use of
LMWHs for initial anticoagulation of PE should be consid-
ered to be safe and effective only in clinically stable
patients. Another noteworthy aspect is that formal au-
thority approval of LMWHs in PE is restricted to tinzapa-
rin, which reflects the international trial status (table 1).
Recently, new anticoagulants have been developed
with more specific characteristics in the inhibition of the
coagulation cascade. These drugs exclusively target either
activated factor II or activated factor X. Clinical investi-
gation has advanced most for ximelagatran/melagatran,
which is an orally administered direct thrombin inhibitor,
and for fondaparinux, a parenterally administered anti-
thrombin-dependent factor Xa inhibitor [11–13].
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Fig. 1. Coagulation cascade and interaction
of antithrombotic drugs. F = Factor.
F XI F XIa
F IX F IXa
F X F Xa
F II F IIa
fibrinogen fibrin crosslinked fibrin





Intrinsic pathway Extrinsic pathway
The clinical trial program of ximelagatran/melagatran
does not comprise studies specifically enrolling patients
with symptomatic PE. Thus, to date there are no data
regarding its efficacy and safety in the initial treatment of
PE. Fondaparinux has been investigated in large trials
evaluating its efficacy and safety in the initial anticoagula-
tion of patients with DVT and of patients with symptom-
atic PE. The trial which investigated treatment of PE
(MATISSE-PE) [13] included more than 2,200 patients,
who were randomized to a body weight-adjusted dose of
fondaparinux (7.5 mg for most patients) or UFH. Both
regimens of initial treatment were followed by VKAs. The
choice of UFH in the control group reflects the interna-
tional standard of care at the time the trial program was
designed (1998/1999).
As it was designed as a noninferiority trial, a safety
margin of +3.5% difference in the efficacy endpoint was
set to define the range of noninferiority. The rate of VTE
recurrence within 90 days was 3.8% for fondaparinux and
5.0% for UFH, respectively. The 1.2% absolute risk
reduction had a 95% confidence interval ranging from
–3.0% to +0.5%, thereby lacking statistically significant
superiority. No significant differences were detected re-
garding major and minor bleeding and mortality. These
results show that a once daily subcutaneous dose of fonda-
parinux is at least as safe and effective as UFH in the ini-
tial anticoagulation of PE. It has to be noted that fonda-
parinux has been studied neither in hemodynamically
unstable patients nor in patients with impaired renal
function. Because of the pharmacological profile of this
entirely synthetic drug with no remaining immunogenici-
ty for HIT-II antibodies and its animal-independent pro-
duction, it may be anticipated that fondaparinux will gain
major importance in the treatment of PE. Approval for
this indication is expected in 2004.
Secondary Prophylaxis
VKAs are the current standard of secondary prophy-
laxis in VTE. Any specifications for treatment, such as
intensity and duration, have been developed from studies
with patients who for the most part had DVT as the pre-
senting event of VTE. By the end of the 1980s, two impor-
tant issues regarding secondary prophylaxis had been sett-
led. Firstly, laboratory monitoring of anticoagulation with
VKA should be done using the international normalized
ratio (INR) rather than prothrombin time (Quick test).
INR corrects for the substantial differences in prothrom-
bin time that occur between thromboplastin preparations
used in different tests. Although this fact has been estab-
lished beyond doubt, the exclusive use of INR to monitor
VKA has so far not become routine practice in many
countries and continues to be an issue in medical educa-
tion. Secondly, after recognition of the issue of anticoagu-
lation intensity ranges, the optimal INR range for second-
ary prophylaxis of venous thromboembolic disease is 2.0–
3.0. A value above 3.0 increases bleeding without improv-
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ing efficacy, while a value below 2.0 is less effective with-
out reducing the risk of bleeding [14, 15]. According to a
recent randomized trial, the moderate range of 2.0–3.0
appears to be sufficient even for patients with VTE and
antiphospholipid syndrome [16], in whom an INR higher
than 3.0 had previously been suggested to be the most effi-
cient prophylaxis [17]. Considering these data, it is now
settled that whenever VKAs are used in the secondary
prophylaxis of VTE, the optimal INR range is 2.0–3.0.
The issue of duration of secondary prophylaxis has
been studied extensively. Although it cannot be reviewed
in detail here, the following principles can be outlined:
(1) The risk of recurrent PE is very low during treat-
ment with VKAs [18].
(2) If secondary prophylaxis is discontinued too early
after the index event, an overshoot of relapses has been
observed [19].
(3) If VKAs are discontinued 3 or 6 months after the
initial event, recurrence will occur with a constant overall
frequency of about 5% per year [19]. The individual risk
of recurrence depends on a combination of transient and
persistent risk factors and may be higher in an individual
patient. It appears to be appropriate to prolong secondary
prophylaxis for subgroups of patients with an increased
risk of recurrence [20].
(4) VKA treatment of patients with VTE with an INR
target range of 2.0–3.0 will cause major bleeds with a con-
stant overall frequency of about 3% per year [15, 21]. The
individual risk of major bleeding may be higher and
depends on a combination of patient characteristics. Pre-
diction models have been developed for the risk estima-
tion in subgroups of patients [22, 23].
There are subgroups of patients for whom randomized
trials proved prolongation of secondary prophylaxis with
VKAs to be beneficial. In a study of secondary prophylax-
is after recurrent VTE, Schulman et al. [24] demonstrated
a benefit for patients allocated to indefinite treatment
after a median follow-up of 4 years. However, the study
data suggested that prolongation beyond 48 months might
lead to inversion of the risk-benefit ratio due to accumu-
lating bleeding episodes [24].
An increased risk of recurrence has also been observed
in patients with VTE not triggered by transient risk fac-
tors or underlying disease, such as trauma, immobiliza-
tion, recent surgery, hormone therapy, pregnancy or can-
cer. Such episodes are termed idiopathic thromboembo-
lism. In 1999, Kearon et al. [25] showed that after a first
idiopathic episode of VTE, prolongation of VKA treat-
ment for up to 14 months yields a positive risk-benefit
ratio when compared to 3 months of treatment. However,
2 years later, Agnelli et al. [26] presented a randomized
controlled follow-up study with the same approach indi-
cating that the group with prolonged secondary prophy-
laxis experienced a rebound in recurrent events after dis-
continuation of medication, which annihilated the benefit
achieved in the first year of treatment. No data have been
published to reconcile these findings. However, there is a
broad consensus that prolonged secondary prophylaxis
after a first event of VTE should only be considered in
patients with an unprovoked episode.
In order to offer prolonged secondary prophylaxis to
patients with idiopathic VTE without increasing the risk
of bleeding, a low-intensity regimen of VKAs (INR 1.5–
2.0) has been tested. Unfortunately, two prospective trials
revealed conflicting results. The comparison of a VKA at
an INR of 1.5–2.0 with placebo showed effectiveness of
this treatment regimen; firm conclusions regarding the
bleeding risk could not be drawn due to a lack of statistical
power for this endpoint [27]. The comparison of a VKA at
an INR of 1.5–2.0 with the traditional intensity of INR
2.0–3.0 revealed a lower efficacy of the former with an
equal bleeding risk, thereby indicating that the low-inten-
sity regimen is not superior [15]. Comparing the event
rates in the low-intensity arm of both trials suggests that
slightly different patient populations were studied. In
summary, the issue of low-intensity VKA regimens has
not been settled yet.
Thrombophilia has been suggested to be a major deter-
minant of the risk of recurrence of VTE [28]. However,
after more than 10 years of clinical research, it has
become clear that a thrombophilic state as assessed by
laboratory testing, even though established as a risk factor
for VTE, does not predict a significantly higher risk of
recurrence [29]. Except for the antiphospholipid syn-
drome, severe antithrombin deficiency and severe protein
C deficiency with a positive family history, prolonged sec-
ondary prophylaxis is not indicated in patients after a first
VTE episode on the basis of a positive thrombophilia test
result alone.
A certain number of patients with VTE are not eligible
for treatment with VKAs. This may be due to low com-
pliance, uncontrolled addictive disease or severe comor-
bidity. The approach of using LMWHs for secondary pro-
phylaxis has been tested for different LMWHs in various
dose regimens ranging from a high-risk prophylactic dose
to a full therapeutic dose. A meta-analysis of these mostly
small trials demonstrated that compared with VKAs,
LMWHs are equally effective and may reduce the number
of bleeding events significantly (up to 60%) [30]. Feasibil-
ity and reimbursement arguments may prevent this ap-
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proach from becoming widespread clinical practice, but
in selected patients ineligible for VKA, administration of
an LMWH is an alternative option. With no consistent
evidence-based recommendation available, an LMWH
dosage of 80–100 IU anti-Xa per kilogram of body weight
once daily appears a reasonable regimen once initial treat-
ment has been completed.
It has to be noted that many of the data discussed
above have been acquired in patients with DVT as the
presenting episode of VTE. Symptomatic PE was present
only in (a minor) part of the study populations. There are
no trials specifically addressing the secondary prophylaxis
of PE. This may prove to be an important aspect for
future developments because evidence has emerged that
the natural history of recurrent disease after PE is not the
same as that after DVT [18]. Ninety percent of patients
relapse with the clinical presentation of their first event.
That means that 90% of recurrences after initial PE epi-
sodes will again be symptomatic PE. In recurrent epi-
sodes, a higher mortality has also been observed for PE as
compared with DVT [18]. However, although continuous
anticoagulation prevents recurrence, a rebound after dis-
continuation results in equal long-term recurrence rates
when extended and short-term duration of VKA is com-
pared [31]. Further evaluation is needed here since so far
the appropriate response to these observations remains
unclear.
Major impact on secondary prophylaxis is expected
from new drug developments in the near future. Ximela-
gatran/melagatran is an orally administered direct throm-
bin inhibitor which was tested in a fixed twice daily dose
over 18 months (THRIVE III study) [12]. After the end of
at least 6 months of secondary prophylaxis, patients with
VTE were randomized to ximelagatran/melagatran or
placebo. There was a relative risk reduction of 83% (2 vs.
12%) for recurrent VTE events. The incidence of major
bleeding was equal to that in the placebo group. Even if
this result was established in patients with DVT as the
primary event, there is no reason for not applying it to
prolonged secondary prophylaxis after PE. However, xi-
melagatran/melagatran causes transient liver enzyme ele-
vations in 5–10% of patients [11, 12]. The nature and
clinical significance of this phenomenon are not yet fully
understood.
Another pharmacological principle is currently under
clinical evaluation in phase III trials. Modification of the
pentasaccharide molecule of fondaparinux led to a new
compound (idraparinux) with a plasma half-life increased
by a factor of more than 3 [32]. This allows stable antico-
agulation with once weekly subcutaneous injections. Two
clinical trials on the treatment of VTE with idraparinux
are currently under way, enrolling 2,200 patients with
DVT and another 2,200 patients with PE. Prolongation of
secondary prophylaxis will also be evaluated.
Systemic Thrombolysis
Systemic thrombolysis in appropriate dosages is able
to rapidly reduce thrombus mass throughout the circula-
tion. In PE, this has been demonstrated by reduction of
the Miller score, improvement of perfusion scan, reduc-
tion of pulmonary artery pressure and improvement of
right ventricular function within 24 h after medication
[33].
It is obvious that these early effects can be beneficial in
patients with acute life-threatening PE, whose short-term
prognosis is determined by the degree of right ventricular
failure due to increased pulmonary artery pressure caused
by obstruction of the pulmonary artery tree by embolic
material. Acute life-threatening PE is understood as circu-
latory arrest and the need for CPR, or formal shock (sys-
tolic arterial pressure !100 mm Hg, heart rate 1100/min)
with or without the need for ventilatory support. From a
number of cohort studies, it can be estimated that mortal-
ity in these patients reaches around 70% when thromboly-
sis is withheld, which outnumbers by far any risk of severe
bleeding even in early postoperative patients [34]. Ob-
viously, this group of patients is not suited for random-
ized controlled trials, and thrombolytic therapy is consid-
ered the treatment of choice [35, 36].
Today, the most common dose regimen is 100 mg of
alteplase administered over 2 h with a front load of 10 or
20 mg. Alternatively, 2 million units of urokinase can be
given over 2–4 h. Under CPR, bolus administration of 2
! 50 mg or 1 ! 100 mg of alteplase may be considered in
order to achieve immediate effects. In postoperative pa-
tients and in patients undergoing CPR, major bleeding
has to be expected and may require vigorous treatment
with transfusion of packed red blood cells, fresh frozen
plasma and platelets. There are some data that show that
bleeding complications can be controlled more successful-
ly than deterioration of right heart failure. As a clinical
decision rule, CPR should not be stopped until (1) the
maximum dose of a thrombolytic agent has been adminis-
tered, and (2) sufficient time has elapsed to allow for effec-
tive thrombolysis and right heart recovery. Bedside trans-
thoracic echocardiography is a helpful tool in guiding
therapy [37, 38].
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Whether the early hemodynamic benefit of systemic
thrombolysis translates into a decrease in mortality in
patients with a wider scope of PE symptoms has been
under investigation since the 1970s. Alteplase as well as
streptokinase and urokinase have been evaluated in dif-
ferent dose and time regimens [33]. Control groups were
treated with UFH in therapeutic dosages. Follow-up for
mortality was 12 months in some trials, but unfortunate-
ly, the more recent alteplase trials only reported 30-day
results. A meta-analysis performed by Dalen et al. [33] in
1997 showed no reduction of mortality with systemic
thrombolysis, neither at 30 days nor at 12 months, but
found an average incidence of intracranial hematoma of
2%, which is higher than in thrombolysis trials of myocar-
dial infarction. Thus, it became evident that a better defi-
nition was needed of the target population beyond those
in shock or under CPR. This required a predictive mea-
sure for increased mortality in patients with PE.
Two large registries independently established that
right ventricular dysfunction as assessed by transthoracic
echocardiography provides such a measure. In the Inter-
national Cooperative Pulmonary Embolism Registry,
right ventricular dysfunction was an independent predic-
tor of death with a hazard ratio of 2.0 [39]. The MAPPET
registry showed that right ventricular dysfunction at pre-
sentation was present in 84% of patients who died, and in
16% of those who survived [34]. In both registries, right
ventricular dysfunction was defined by contractility pat-
terns of the right heart (RVESP 1 30 mm, paradoxical
septum movement, right ventricular akinesia or dyskine-
sia) rather than by pulmonary artery pressure. PE patients
with these criteria appeared most likely to benefit from
thrombolysis.
Konstantinides et al. [40] conducted a randomized
controlled trial from 1997 to 2001, enrolling 256 patients
with submassive PE at 49 study sites. Hemodynamically
stable patients with significant right ventricular dysfunc-
tion were randomized to receive either 100 mg of alte-
plase over 2 h or placebo. The primary endpoint was a
composite of death or treatment escalation. Treatment
escalation was defined by infusion of catecholamines, sec-
ondary open-label thrombolysis, endotrachel intubation,
CPR or mechanical thrombus fragmentation. Patients
were followed until hospital discharge. For this composite
endpoint, a statistically significant risk reduction of 55%
for alteplase was found. The incidence of major bleeding
was extraordinarily low (2.3%), with no cases of intracra-
nial hemorrhage.
The interpretation of this study remains controversial.
The authors claim that this study proves the benefit of
systemic thrombolysis in well-defined patients and that
thrombolysis should therefore be considered routinely as
an option in those patients [40]. Opponents argue that the
difference in outcome was exclusively due to the frequen-
cy of secondary thrombolysis within the first 4 days and to
a treatment escalation which had no objective measure
but was left entirely to the discretion of the attending phy-
sician. This is of particular importance since clinical
observation de facto unblinded treatment assignment a
few hours after administration of the study drug. There
was no difference in mortality or documented recurrent
PE. In addition, the long study duration despite a large
number of centers raises doubts as to whether the study
population represents the majority of patients with PE
and right ventricular dysfunction. With this criticism in
mind, it may be concluded from the trial that in very care-
fully selected patients with PE and right ventricular func-
tion, systemic thrombolysis can ameliorate the severity of
the early course of the disease, at least in the perception of
the attending physician. As in previous trials, an impact
on mortality was not shown.
Mechanical Thrombus Fragmentation with or
without Local Thrombolysis
Several authors have convincingly demonstrated that
pulmonary artery thrombus burden can be reduced by
mechanical thrombus fragmentation using catheter de-
vices with or without local thrombolysis, thereby ensuring
rapid right ventricular recovery [41–45]. There are no
data as to whether this approach is more effective than
systemic thrombolysis. However, it certainly does require
more logistics, equipment and material. It does not ap-
pear likely that any prospective study will further investi-
gate the potential value of this regimen. It may still be
argued that mechanical thrombus fragmentation can be
beneficial in hemodynamically instable patients with se-
vere contraindications against systemic thrombolysis,
such as early postoperative patients, particularly after
CNS surgery or in the immediate postpartum period.
Surgery
Although a procedure with a history of more than 150
years, emergency open lung pulmonary thrombectomy
should be avoided. In a remarkable prospective compari-
son with systemic thrombolysis, no advantage of heart-
lung machine-assisted thrombectomy could be found
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Table 2. Stage-adapted therapy of PE
Clinical presentation of PE Principles of therapy
Cardiac arrest requiring CPR emergency systemic thrombolysis
Hemodynamic shock and need for
catecholamines
systemic thrombolysis, or mechanical thrombus
fragmentation with/without local thrombolysis if
available
Right ventricular dysfunction with
hemodynamic stability
anticoagulation and intensive care; systemic throm-
bolysis may be considered when bleeding risk is low
Normal right ventricular function
and hemodynamic stability
anticoagulation; outpatient treatment may be con-
sidered if backup facilities are available
[46]. It requires even more logistics than mechanical
thrombus fragmentation. Theoretically, it could be an
option for a patient under CPR who cannot be stabilized
by systemic thrombolysis; however, to substantiate this
concept, at least a couple of such cases resulting in full
recovery need to be reported.
Stage-Adapted Therapeutic Concept
The presentation of patients with PE may cover a
broad clinical spectrum from almost symptom-free dis-
ease to rapidly deteriorating courses or sudden death.
This spectrum can be met by a range of therapeutic
modalities. The prerequisite for the choice of appropriate
treatment is a risk assessment which takes into account
both the prognosis of the disease and the side effects of
treatment. This will minimize the risk of subjecting a
patient with an excellent prognosis to high-risk treatment,
or of withholding procedures from patients who have
almost no chance of survival unless treated vigorously.
From large registries, the main short-term prognostic fac-
tors have been established to be hemodynamic parame-
ters. Four prognostic classes may be differentiated:
(1) Cardiac arrest due to right heart failure obviously
carries the highest mortality and requires CPR and inten-
sive care. In most cases, the diagnosis can be made from
the history in conjunction with bedside echocardiogra-
phy. Emergency systemic thrombolysis should be per-
formed under CPR regardless of any contraindication.
Preferably, a bolus regimen of alteplase or urokinase
should be administered. Major bleeding has to be ex-
pected and sufficient amounts of blood products have to
be prepared.
(2) Prognosis is similarly poor for patients in shock, i.e.
with a heart rate above 100/min and a systolic arterial
pressure below 100 mm Hg. They are likely to deteriorate
further within the next few hours and will likely require
ventilatory support and catecholamines. Thrombolysis
should be performed, e.g. 100 mg of alteplase over 2 h
with an initial bolus of 20 mg. If there is local expertise in
mechanical thrombolysis, and it is available within 1 h,
this option may be chosen for a patient with an exception-
ally high bleeding risk.
(3) Hemodynamically stable patients should be evalu-
ated with transthoracic echocardiography in order to
assess prognosis. Patients with right ventricular dysfunc-
tion have a poorer prognosis than those with normal right
ventricular function. Most patients will have hypoxia and
tachycardia without hypotension. They must be treated
with anticoagulants and monitored in intensive care
units. If right ventricular function and tachycardia do not
improve within 6–12 (24) h, systemic thrombolysis may
be considered with the aim of hastening recovery. Since
no effect of thrombolysis on mortality has been demon-
strated in these patients, contraindications against throm-
bolysis should be observed. Informed consent should be
obtained.
(4) Hemodynamically stable patients with normal right
ventricular function on echocardiography have an excel-
lent short-term prognosis. The majority of PE patients
will present in this state. Anticoagulation is mandatory,
preferably with LMWHs if renal function is normal.
Intensive care is not generally necessary. If transthoracic
echocardiography shows normal pulmonary artery pres-
sure (as assessed by tricuspid valve pressure gradient),
even outpatient treatment can be considered, although
then a stable network of backup facilities has to be avail-
able [47].
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In summary, early assessment of the patient’s short-
term prognosis is the key to a stage-adapted treatment
concept. Beside clinical evaluation, echocardiography is
the most important tool for risk stratification. It should be
available as a bedside test in critically ill patients as well as
a routine diagnostic procedure in emergency rooms. Once
the diagnosis of PE has been established, echocardiogra-
phy provides the basis for the principal decisions regard-
ing both medical treatment and the setting of caregiving
(table 2).
References
1 Barritt DW, Jordan SC: Anticoagulant drugs in
the treatment of pulmonary embolism. A con-
trolled trial. Lancet 1960;i:1309–1312.
2 Basu D, Gallus A, Hirsh J, Cade J: A prospec-
tive study of the value of monitoring heparin
treatment with the activated partial thrombo-
plastin time. N Engl J Med 1972;287:324–
327.
3 Kearon C: Drug trials that have influenced our
practice in the treatment of venous thrombo-
embolism. Thromb Haemost 1997;78:553–
557.
4 Bernardi E, Piccioli A, Oliboni G, Zuin R,
Girolami A, Prandoni P: Nomograms for the
administration of unfractionated heparin in
the initial treatment of acute thromboembo-
lism – an overview. Thromb Haemost 2000;84:
22–26.
5 Kearon C, Harrison L, Crowther M, Ginsberg
JS: Optimal dosing of subcutaneous unfrac-
tionated heparin for the treatment of deep vein
thrombosis. Thromb Res 2000;97:395–403.
6 Gallus A, Jackaman J, Tillett J, Mills W, Wy-
cherley A: Safety and efficacy of warfarin
started early after submassive venous thrombo-
sis or pulmonary embolism. Lancet 1986;
ii:1293–1296.
7 Brandjes DP, Heijboer H, Buller HR, de Rijk
M, Jagt H, ten Cate JW: Acenocoumarol and
heparin compared with acenocoumarol alone
in the initial treatment of proximal-vein
thrombosis. N Engl J Med 1992;327:1485–
1489.
8 Low-molecular-weight heparin in the treat-
ment of patients with venous thromboembo-
lism. The Columbus Investigators. N Engl J
Med 1997;337:657–662.
9 Simonneau G, Sors H, Charbonnier B, et al: A
comparison of low-molecular-weight heparin
with unfractionated heparin for acute pulmo-
nary embolism. The THESEE Study Group.
Tinzaparine ou Heparine Standard: Evalua-
tions dans l’Embolie Pulmonaire. N Engl J
Med 1997;337:663–669.
10 van Den Belt AG, Prins MH, Lensing AW, et
al: Fixed dose subcutaneous low molecular
weight heparins versus adjusted dose unfrac-
tionated heparin for venous thromboembo-
lism. Cochrane Database Syst Rev 2000;(2):
CD001100.
11 Huisman MV: Efficacy and safety of the oral
direct thrombin inhibitor ximelagatran com-
pared with current standard therapy for acute
symptomatic deep vein thrombosis, with or
without pulmonary embolism: A randomized,
double-blind, multinational study. J Thromb
Haemost 2003;1(suppl 1):OC003.
12 Eriksson H, Wahlander K, Lundström T, Bil-
ling-Clason S, Schulman S, Investigators TI:
Extended secondary prevention with the oral
direct thrombin inhibitor ximelagatran for 18
months after 6 months of anticoagulation in
patients with venous thromboembolism: A ran-
domized, placebo-controlled trial. J Thromb
Haemost 2003;1(suppl 1):OC005.
13 The Matisse Investigators: The MATISSE-PE
trial, a multicenter, randomized, open study
comparing once-daily fondaparinux (Arixtra®)
with adjusted-dose intravenous unfractionated
heparin (UFH) in the initial treatment of acute
symptomatic pulmonary embolism (PE). J
Thromb Haemost 2003;1(suppl 1):OC331.
14 Hirsh J, Dalen J, Anderson DR, et al: Oral anti-
coagulants: Mechanism of action, clinical effec-
tiveness, and optimal therapeutic range. Chest
2001;119(suppl 1):8S–21S.
15 Kearon C, Ginsberg JS, Kovacs MJ, et al: Com-
parison of low-intensity warfarin therapy with
conventional-intensity warfarin therapy for
long-term prevention of recurrent venous
thromboembolism. N Engl J Med 2003;349:
631–639.
16 Crowther MA, Ginsberg JS, Julian J, et al: A
comparison of two intensities of warfarin for
the prevention of recurrent thrombosis in pa-
tients with the antiphospholipid antibody syn-
drome. N Engl J Med 2003;349:1133–1138.
17 Khamashta MA, Cuadrado MJ, Mujic F, Taub
NA, Hunt BJ, Hughes GRV: The management
of thrombosis in the antiphospholipid-anti-
body syndrome. N Engl J Med 1995;332:993–
997.
18 Douketis JD, Kearon C, Bates S, Duku EK,
Ginsberg JS: Risk of fatal pulmonary embolism
in patients with treated venous thromboembo-
lism. JAMA 1998;279:458–462.
19 Schulman S, Rhedin AS, Lindmarker P, et al: A
comparison of six weeks with six months of
oral anticoagulant therapy after a first episode
of venous thromboembolism. Duration of An-
ticoagulation Trial Study Group. N Engl J Med
1995;332:1661–1665.
20 Schulman S: Care of patients receiving long-
term anticoagulant therapy. N Engl J Med
2003;349:675–683.
21 Hull R, Hirsh J, Jay R, et al: Different intensi-
ties of oral anticoagulant therapy in the treat-
ment of proximal-vein thrombosis. N Engl J
Med 1982;307:1676–1681.
22 Beyth RJ, Quinn LM, Landefeld S: Prospective
evaluation of an index for predicting the risk of
major bleeding in outpatients treated with war-
farin. Am J Med 1998;105:91–99.
23 Kuijer PM, Hutten BA, Prins MH, Buller HR:
Prediction of the risk of bleeding during antico-
agulant treatment for venous thromboembo-
lism. Arch Intern Med 1999;159:457–460.
24 Schulman S, Granqvist S, Holmstrom M, et al:
The duration of oral anticoagulant therapy af-
ter a second episode of venous thromboembo-
lism. The Duration of Anticoagulation Trial
Study Group. N Engl J Med 1997;336:393–
398.
25 Kearon C, Gent M, Hirsh J, et al: A compari-
son of three months of anticoagulation with
extended anticoagulation for a first episode of
idiopathic venous thromboembolism. N Engl J
Med 1999;340:901–907.
26 Agnelli G, Prandoni P, Santamaria MG, et al:
Three months versus one year of oral anticoag-
ulant therapy for idiopathic deep venous
thrombosis. Warfarin Optimal Duration Ital-
ian Trial Investigators. N Engl J Med 2001;
345:165–169.
27 Ridker PM, Goldhaber SZ, Danielson E, et al:
Long-term, low-intensity warfarin therapy for
the prevention of recurrent venous thrombo-
embolism. N Engl J Med 2003;348:1425–
1434.
28 Seligsohn U, Lubetsky A: Genetic susceptibili-
ty to venous thrombosis. N Engl J Med 2001;
344:1222–1231.
29 Baglin T, Luddington R, Brown K, Baglin C:
Incidence of recurrent venous thromboembo-
lism in relation to clinical and thrombophilic
risk factors: Prospective cohort study. Lancet
2003;362:523–526.
30 van der Heijden JF, Hutten BA, Büller HR,
Prins MH: Vitamin K antagonists or low-mo-
lecular-weight heparin for the long term treat-
ment of symptomatic venous thromboembo-
lism. Cochrane Database Syst Rev 2002;(1):
CD002001.
31 Agnelli G, Prandoni P, Becattini C, et al: Ex-
tended oral anticoagulant therapy after a first
episode of pulmonary embolism. Ann Intern
Med 2003;139:19–25.
32 Koopman MM, Buller HR: Short- and long-
acting synthetic pentasaccharides. J Intern
Med 2003;254:335–342.
568 Respiration 2003;70:559–568 Schellong/Schmidt
33 Dalen JE, Alpert JS, Hirsch J: Thrombolytic
therapy for pulmonary embolism: Is it effec-
tive? Is it safe? When is it indicated? Arch
Intern Med 1997;157:2550–2556.
34 Kasper W, Konstantinides S, Geibel A, et al:
Management strategies and determinants of
outcome in acute major pulmonary embolism:
Results of a multicenter registry. J Am Coll
Cardiol 1997;30:1165–1171.
35 Arcasoy SM, Vachani A: Local and systemic
thrombolytic therapy for acute venous throm-
boembolism. Clin Chest Med 2003;24:73–91.
36 Wood KE: Major pulmonary embolism: Re-
view of a pathophysiologic approach to the
golden hour of hemodynamically significant
pulmonary embolism. Chest 2002;121:877–
905.
37 Kasper W, Konstantinides S, Geibel A, Tiede
N, Krause T, Just H: Prognostic significance of
right ventricular afterload stress detected by
echocardiography in patients with clinically
suspected pulmonary embolism. Heart 1997;
77:346–349.
38 Kasper W, Geibel A, Tiede N, et al: Distin-
guishing between acute and subacute massive
pulmonary embolism by conventional and
Doppler echocardiography. Br Heart J 1993;
70:352–356.
39 Goldhaber SZ, Visani L, De Rosa M: Acute
pulmonary embolism: Clinical outcomes in the
International Cooperative Pulmonary Embo-
lism Registry (ICOPER). Lancet 1999;353:
1386–1389.
40 Konstantinides S, Geibel A, Heusel G, Hein-
rich F, Kasper W, the Management Strategies
and Prognosis of Pulmonary Embolism-3 Trial
Investigators: Heparin plus alteplase compared
with heparin alone in patients with submassive
pulmonary embolism. N Engl J Med 2002;347:
1143–1150.
41 Reekers JA, Baarslag HJ, Koolen MG, Van
Delden O, Van Beek EJ: Mechanical thrombec-
tomy for early treatment of massive pulmonary
embolism. Cardiovasc Intervent Radiol 2003;
26:246–250.
42 Muller-Hulsbeck S, Brossmann J, Jahnke T, et
al: Mechanical thrombectomy of major and
massive pulmonary embolism with use of the
Amplatz thrombectomy device. Invest Radiol
2001;36:317–322.
43 Fava M, Loyola S, Huete I: Massive pulmonary
embolism: Treatment with the hydrolyser
thrombectomy catheter. J Vasc Interv Radiol
2000;11:1159–1164.
44 Schmitz-Rode T, Janssens U, Duda SH, Erley
CM, Gunther RW: Massive pulmonary embo-
lism: Percutaneous emergency treatment by
pigtail rotation catheter. J Am Coll Cardiol
2000;36:375–380.
45 Murphy JM, Mulvihill N, Mulcahy D, Foley B,
Smiddy P, Molloy MP: Percutaneous catheter
and guidewire fragmentation with local admin-
istration of recombinant tissue plasminogen ac-
tivator as a treatment for massive pulmonary
embolism. Eur Radiol 1999;9:959–964.
46 Gulba DC, Schmid C, Borst HG, Lichtlen P,
Dietz R, Luft FC: Medical compared with sur-
gical treatment for massive pulmonary embo-
lism. Lancet 1994;343:576–577.
47 Beer JH, Burger M, Gretener S, Bernard-Bagat-
tini S, Bounameaux H: Outpatient treatment of
pulmonary embolism is feasible and safe in a
substantial proportion of patients. J Thromb
Haemost 2003;1:186–187.
